Blood-based biomarkers in patients with non-small cell lung cancer treated with immune checkpoint blockade

Yo-Ting Tsai,Jeffrey Schlom,Renee N. Donahue

DOI: https://doi.org/10.1186/s13046-024-02969-1

IF: 12.658

2024-03-18

Journal of Experimental & Clinical Cancer Research

Abstract:The paradigm of non-small cell lung cancer (NSCLC) treatment has been profoundly influenced by the development of immune checkpoint inhibitors (ICI), but the range of clinical responses observed among patients poses significant challenges. To date, analyses of tumor biopsies are the only parameter used to guide prognosis to ICI therapy. Tumor biopsies, however, are often difficult to obtain and tissue-based biomarkers are limited by intratumoral heterogeneity and temporal variability. In response, there has been a growing emphasis on the development of "liquid biopsy"‒ derived biomarkers, which offer a minimally invasive means to dynamically monitor the immune status of NSCLC patients either before and/or during the course of treatment. Here we review studies in which multiple blood-based biomarkers encompassing circulating soluble analytes, immune cell subsets, circulating tumor DNA, blood-based tumor mutational burden, and circulating tumor cells have shown promising associations with the clinical response of NSCLC patients to ICI therapy. These investigations have unveiled compelling correlations between the peripheral immune status of patients both before and during ICI therapy and patient outcomes, which include response rates, progression-free survival, and overall survival. There is need for rigorous validation and standardization of these blood-based assays for broader clinical application. Integration of multiple blood-based biomarkers into comprehensive panels or algorithms also has the potential to enhance predictive accuracy. Further research aimed at longitudinal monitoring of circulating biomarkers is also crucial to comprehend immune dynamics and resistance mechanisms and should be used alongside tissue-based methods that interrogate the tumor microenvironment to guide treatment decisions and may inform on the development of novel therapeutic strategies. The data reviewed here reinforce the opportunity to refine patient stratification, optimize treatments, and improve outcomes not only in NSCLC but also in the wider spectrum of solid tumors undergoing immunotherapy.

oncology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is: during the treatment of non - small - cell lung cancer (NSCLC) patients with immune checkpoint inhibitors (ICI), to discover biomarkers that can predict clinical responses through blood tests. Specifically, the article explores a variety of blood - based biomarkers, such as circulating soluble analytes, immune cell subsets, circulating tumor DNA, blood - based tumor mutational burden (bTMB), and circulating tumor cells (CTCs), and the relationships between these markers and the clinical responses of NSCLC patients to ICI treatment. The paper emphasizes the potential of these biomarkers in predicting patients' treatment response rates, progression - free survival (PFS) and overall survival (OS), aiming to optimize patient stratification and treatment selection through these non - invasive detection methods, thereby improving treatment outcomes.

The article also points out the limitations of current tissue - based biomarkers (such as PD - L1 expression and tumor mutational burden TMB), including difficulties in acquisition, intratumor heterogeneity and temporal variability, etc. These problems limit their effectiveness in clinical applications. Therefore, the development of blood - based biomarkers has become an important direction of current research to overcome the above limitations and support personalized treatment for NSCLC patients.